Home › Companies › Alnylam Pharmaceuticals, Inc. › 2025-2026
Compiled from SEC Form N-PX filings and Alnylam Pharmaceuticals, Inc.’s Form 8-K, filed May 27, 2026 (Item 5.07 on EDGAR). Page generated October 18, 2026.
Meeting of May 20, 2026: 5 items on Alnylam Pharmaceuticals, Inc.’s Form 8-K, filed May 27, 2026: 3 elected · 2 approved.
None.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Explore Alnylam Pharmaceuticals, Inc. in the interactive database Compare manager voting policies
These tallies are Alnylam Pharmaceuticals, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 27, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Stuart A. Arbuckle | 115,269,659 | 5,068,463 | 28,296 | -- | 5,450,286 | 96% | Elected | — |
| Elect Director: Yvonne L. Greenstreet, M.D. | 119,787,307 | 513,049 | 66,062 | -- | 5,450,286 | 99.5% | Elected | — |
| Elect Director: Elliott Sigal, M.D., Ph.D. | 107,495,421 | 12,844,836 | 26,161 | -- | 5,450,286 | 89% | Elected | — |
| The terms of office of the following directors continued after the Annual Meeting: Dennis A. Ausiello, M.D. | 111,772,389 | 8,552,534 | 41,495 | -- | 5,450,286 | 93% | Approved | — |
| 3. The appointment by the Company's Board of Directors of PricewaterhouseCoopers LLP as the Company's independent auditors for the fiscal year ending December 31, 2026 | 119,847,735 | 5,937,274 | 31,695 | -- | 0 | 95% | Approved | — |
Source: Alnylam Pharmaceuticals, Inc., Form 8-K, filed with the SEC on May 27, 2026 — read the filing on EDGAR.
Each item below shows how the 680 asset managers that disclosed a Alnylam Pharmaceuticals, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Alnylam Pharmaceuticals, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 8 wordings of this item as funds reported it.
89% Majority: yes · of votes cast
Description as filed by funds: To elect the following nominees as Class I directors of Alnylam: Elliott Sigal, M.D., Ph.D.
Alnylam Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Elliott Sigal, M.D., Ph.D.”): 107,495,421 for, 12,844,836 against, per its Form 8-K filed May 27, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The Company's stockholders re-elected the three persons listed below as Class I directors, each to serve until the Company's 2029 annual meeting of stockholders or until his or her successor is duly elected and qualified.”
Support: 89% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 154 asset managers below reported 68,794,831 for, 5,761,800 against, 9,950 abstained, 112 not voted.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 14,748,186 | 103 | 0 | 0 | For |
| Fidelity | 13,032,449 | 0 | 0 | 0 | For |
| Capital Group | 12,701,026 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 4,184,185 | 0 | 0 | Against |
| BlackRock | 4,018,657 | 0 | 0 | 0 | For |
| Invesco | 3,900,892 | 0 | 0 | 0 | For |
| JPMorgan | 3,811,548 | 0 | 0 | 0 | For |
| AMCAP FUND | 3,744,659 | 0 | 0 | 0 | For |
| INVESTMENT CO OF AMERICA | 1,947,787 | 0 | 0 | 0 | For |
| Dodge & Cox | 1,464,041 | 0 | 0 | 0 | For |
| American Century | 1,291,092 | 0 | 0 | 0 | For |
| Jackson National | 408,600 | 610,709 | 0 | 0 | Mixed |
| NEW ECONOMY FUND | 867,315 | 0 | 0 | 0 | For |
| Charles Schwab | 648,690 | 0 | 0 | 0 | For |
| Federated Hermes | 487,257 | 0 | 0 | 0 | For |
| Legg Mason | 397,884 | 0 | 0 | 0 | For |
| First Trust | 377,110 | 0 | 0 | 0 | For |
| MFS | 338,575 | 0 | 0 | 0 | For |
| State Street | 944 | 332,986 | 0 | 0 | Against |
| Voya | 313,791 | 0 | 0 | 0 | For |
| TIAA | 311,189 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 251,940 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 235,593 | 0 | 0 | 0 | For |
| Equitable | 193,366 | 38,126 | 0 | 0 | Mixed |
| ProShares | 183,405 | 0 | 0 | 0 | For |
Showing the 25 largest of 154 asset managers. See all 154 in the interactive database.
Combines 6 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Description as filed by funds: To elect the following nominees as Class I directors of Alnylam: Stuart A. Arbuckle
Alnylam Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Stuart A. Arbuckle”): 115,269,659 for, 5,068,463 against, per its Form 8-K filed May 27, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The Company's stockholders re-elected the three persons listed below as Class I directors, each to serve until the Company's 2029 annual meeting of stockholders or until his or her successor is duly elected and qualified.”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 154 asset managers below reported 70,281,402 for, 4,275,228 against, 9,950 abstained, 112 not voted.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 14,748,245 | 44 | 0 | 0 | For |
| Fidelity | 13,032,449 | 0 | 0 | 0 | For |
| Capital Group | 12,701,026 | 0 | 0 | 0 | For |
| T. Rowe Price | 991,003 | 3,193,182 | 0 | 0 | Mixed |
| BlackRock | 4,018,657 | 0 | 0 | 0 | For |
| Invesco | 3,900,892 | 0 | 0 | 0 | For |
| JPMorgan | 3,811,548 | 0 | 0 | 0 | For |
| AMCAP FUND | 3,744,659 | 0 | 0 | 0 | For |
| INVESTMENT CO OF AMERICA | 1,947,787 | 0 | 0 | 0 | For |
| Dodge & Cox | 1,464,041 | 0 | 0 | 0 | For |
| American Century | 1,291,092 | 0 | 0 | 0 | For |
| Jackson National | 408,600 | 610,709 | 0 | 0 | Mixed |
| NEW ECONOMY FUND | 867,315 | 0 | 0 | 0 | For |
| Charles Schwab | 648,690 | 0 | 0 | 0 | For |
| Federated Hermes | 487,257 | 0 | 0 | 0 | For |
| Legg Mason | 397,884 | 0 | 0 | 0 | For |
| First Trust | 377,110 | 0 | 0 | 0 | For |
| MFS | 338,575 | 0 | 0 | 0 | For |
| State Street | 333,930 | 0 | 0 | 0 | For |
| Voya | 313,791 | 0 | 0 | 0 | For |
| TIAA | 311,189 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 251,940 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 235,593 | 0 | 0 | 0 | For |
| Equitable | 231,492 | 0 | 0 | 0 | For |
| ProShares | 183,405 | 0 | 0 | 0 | For |
Showing the 25 largest of 154 asset managers. See all 154 in the interactive database.
Combines 7 wordings of this item as funds reported it.
99.5% Majority: yes · of votes cast
Description as filed by funds: To elect the following nominees as Class I directors of Alnylam: Yvonne L. Greenstreet, M.D.
Alnylam Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Yvonne L. Greenstreet, M.D.”): 119,787,307 for, 513,049 against, per its Form 8-K filed May 27, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The Company's stockholders re-elected the three persons listed below as Class I directors, each to serve until the Company's 2029 annual meeting of stockholders or until his or her successor is duly elected and qualified.”
Support: 99.5% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 154 asset managers below reported 74,494,553 for, 62,075 against, 9,950 abstained, 112 not voted.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 14,748,284 | 3 | 0 | 0 | For |
| Fidelity | 13,032,449 | 0 | 0 | 0 | For |
| Capital Group | 12,701,026 | 0 | 0 | 0 | For |
| T. Rowe Price | 4,184,185 | 0 | 0 | 0 | For |
| BlackRock | 4,018,657 | 0 | 0 | 0 | For |
| Invesco | 3,900,892 | 0 | 0 | 0 | For |
| JPMorgan | 3,811,548 | 0 | 0 | 0 | For |
| AMCAP FUND | 3,744,659 | 0 | 0 | 0 | For |
| INVESTMENT CO OF AMERICA | 1,947,787 | 0 | 0 | 0 | For |
| Dodge & Cox | 1,464,041 | 0 | 0 | 0 | For |
| American Century | 1,291,092 | 0 | 0 | 0 | For |
| Jackson National | 1,019,309 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 867,315 | 0 | 0 | 0 | For |
| Charles Schwab | 648,690 | 0 | 0 | 0 | For |
| Federated Hermes | 487,257 | 0 | 0 | 0 | For |
| Legg Mason | 397,884 | 0 | 0 | 0 | For |
| First Trust | 377,110 | 0 | 0 | 0 | For |
| MFS | 338,575 | 0 | 0 | 0 | For |
| State Street | 333,930 | 0 | 0 | 0 | For |
| Voya | 313,791 | 0 | 0 | 0 | For |
| TIAA | 311,189 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 251,940 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 235,593 | 0 | 0 | 0 | For |
| Equitable | 201,362 | 30,130 | 0 | 0 | Mixed |
| ProShares | 183,405 | 0 | 0 | 0 | For |
Showing the 25 largest of 154 asset managers. See all 154 in the interactive database.
Combines 8 wordings of this item as funds reported it.
96% Fund and manager reports combined; may count the same shares twice · no official result
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 14,748,243 | 46 | 0 | 0 | For |
| Fidelity | 13,032,449 | 0 | 0 | 0 | For |
| Capital Group | 12,701,026 | 0 | 0 | 0 | For |
| T. Rowe Price | 3,975,770 | 208,415 | 0 | 0 | For |
| BlackRock | 4,018,657 | 0 | 0 | 0 | For |
| Invesco | 3,392,831 | 508,061 | 0 | 0 | Mixed |
| JPMorgan | 3,811,548 | 0 | 0 | 0 | For |
| AMCAP FUND | 3,744,659 | 0 | 0 | 0 | For |
| INVESTMENT CO OF AMERICA | 1,947,787 | 0 | 0 | 0 | For |
| Dodge & Cox | 1,464,041 | 0 | 0 | 0 | For |
| American Century | 1,291,092 | 0 | 0 | 0 | For |
| Jackson National | 1,019,309 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 867,315 | 0 | 0 | 0 | For |
| Charles Schwab | 648,690 | 0 | 0 | 0 | For |
| Federated Hermes | 487,257 | 0 | 0 | 0 | For |
| Legg Mason | 397,884 | 0 | 0 | 0 | For |
| First Trust | 377,110 | 0 | 0 | 0 | For |
| MFS | 338,575 | 0 | 0 | 0 | For |
| State Street | 333,930 | 0 | 0 | 0 | For |
| Voya | 313,791 | 0 | 0 | 0 | For |
| TIAA | 311,189 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 251,940 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 235,593 | 0 | 0 | 0 | For |
| Equitable | 231,492 | 0 | 0 | 0 | For |
| ProShares | 183,405 | 0 | 0 | 0 | For |
Fund voting reports, all 148 managers: 73,546,401 for, 843,838 against, 9,950 abstained, 112 not voted. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 14,084,931 | 0 | 0 | 0 | For |
| Capital Group | 10,822,295 | 0 | 0 | 0 | For |
| Capital Research Global Investors | 9,449,428 | 0 | 0 | 0 | For |
| T. Rowe Price | 6,282,021 | 310,421 | 0 | 0 | For |
| BlackRock | 5,509,921 | 0 | 0 | 0 | For |
| State Street | 2,779,286 | 3,361 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 2,670,197 | 0 | 0 | 0 | For |
| Wellington | 1,852,421 | 0 | 0 | 0 | For |
| Dodge & Cox | 1,815,428 | 0 | 0 | 0 | For |
| American Century | 1,605,554 | 0 | 0 | 0 | For |
| Vanguard | 1,199,059 | 0 | 0 | 0 | For |
| Clearbridge Investments, LLC | 1,113,021 | 0 | 0 | 0 | For |
| Invesco | 85,524 | 835,972 | 0 | 0 | Mixed |
| BAILLIE GIFFORD & CO LTD | 871,986 | 0 | 0 | 0 | For |
| BAILLIE GIFFORD OVERSEAS LTD | 809,469 | 0 | 0 | 0 | For |
| Northern Trust | 752,082 | 0 | 0 | 0 | For |
| Charles Schwab | 737,661 | 0 | 0 | 0 | For |
| Two Sigma | 696,784 | 0 | 0 | 0 | For |
| Federated Hermes | 673,603 | 4,088 | 0 | 0 | For |
| DE Shaw | 602,674 | 0 | 0 | 0 | For |
| Amundi | 0 | 579,094 | 0 | 0 | Against |
| Legal & General Investment Management Ltd | 0 | 558,570 | 0 | 0 | Against |
| MARSHALL WACE, LLP | 556,881 | 0 | 0 | 0 | For |
| JPMorgan | 523,476 | 0 | 0 | 0 | For |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 515,340 | 0 | 0 | 0 | For |
Institutional-manager reports, all 566 managers: 79,917,714 for, 4,743,196 against, 41 abstained, 7,623 not voted. Showing the 25 largest; see all in the interactive database.
Combines 6 wordings of this item as funds reported it.
95% Approved · of votes cast
Description as filed by funds: To ratify the appointment of PricewaterhouseCoopers LLP, an independent registered public accounting firm, as Alnylam's independent auditors for the fiscal year ending December 31, 2026.
Alnylam Pharmaceuticals, Inc.’s own tally for this item (“3. The appointment by the Company's Board of Directors of PricewaterhouseCoopers LLP as the Company's independent auditors for the fiscal year ending December 31, 2026”): 119,847,735 for, 5,937,274 against — passed, per its Form 8-K filed May 27, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's stockholders ratified the appointment by the Company's Board of Directors of PricewaterhouseCoopers LLP as the Company's independent auditors for the fiscal year ending December 31, 2026.”
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 154 asset managers below reported 73,845,890 for, 710,740 against, 9,950 abstained, 112 not voted.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 14,088,432 | 659,857 | 0 | 0 | For |
| Fidelity | 13,032,449 | 0 | 0 | 0 | For |
| Capital Group | 12,701,026 | 0 | 0 | 0 | For |
| T. Rowe Price | 4,184,185 | 0 | 0 | 0 | For |
| BlackRock | 4,018,657 | 0 | 0 | 0 | For |
| Invesco | 3,900,892 | 0 | 0 | 0 | For |
| JPMorgan | 3,811,548 | 0 | 0 | 0 | For |
| AMCAP FUND | 3,744,659 | 0 | 0 | 0 | For |
| INVESTMENT CO OF AMERICA | 1,947,787 | 0 | 0 | 0 | For |
| Dodge & Cox | 1,464,041 | 0 | 0 | 0 | For |
| American Century | 1,291,092 | 0 | 0 | 0 | For |
| Jackson National | 1,019,309 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 867,315 | 0 | 0 | 0 | For |
| Charles Schwab | 648,690 | 0 | 0 | 0 | For |
| Federated Hermes | 487,257 | 0 | 0 | 0 | For |
| Legg Mason | 397,884 | 0 | 0 | 0 | For |
| First Trust | 377,110 | 0 | 0 | 0 | For |
| MFS | 338,575 | 0 | 0 | 0 | For |
| State Street | 333,919 | 11 | 0 | 0 | For |
| Voya | 313,791 | 0 | 0 | 0 | For |
| TIAA | 311,189 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 251,940 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 235,593 | 0 | 0 | 0 | For |
| Equitable | 231,492 | 0 | 0 | 0 | For |
| ProShares | 183,405 | 0 | 0 | 0 | For |
Showing the 25 largest of 154 asset managers. See all 154 in the interactive database.
Not shown here: this season’s fund filings also report 1 item from the meeting of May 8, 2025, which belongs to the 2024-2025 season. A meeting outside this season’s July 1 to June 30 window is not counted in this page’s items or in its totals of asset managers and fund votes.
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 132,376,000 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 11.14% |
| 2 | Fidelity | 9.85% |
| 3 | Capital Group | 9.59% |
| 4 | T. Rowe Price | 3.16% |
| 5 | BlackRock | 3.04% |
| 6 | Invesco | 2.95% |
| 7 | JPMorgan | 2.88% |
| 8 | AMCAP FUND | 2.83% |
| 9 | INVESTMENT CO OF AMERICA | 1.47% |
| 10 | Dodge & Cox | 1.11% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 10.64% |
| 2 | Capital Group | 8.18% |
| 3 | Capital Research Global Investors | 7.14% |
| 4 | T. Rowe Price | 4.98% |
| 5 | BlackRock | 4.16% |
| 6 | State Street | 2.10% |
| 7 | GEODE CAPITAL MANAGEMENT, LLC | 2.02% |
| 8 | Wellington | 1.40% |
| 9 | Dodge & Cox | 1.37% |
| 10 | American Century | 1.21% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| FMR (Fidelity) | 11.01% | 13F |
| Capital World Investors | 8.25% | 13G |
| BlackRock | 7.89% | 13F |
| Capital Research Global Investors | 7.15% | 13G |
| JPMorgan Chase | 4.78% | 13F |
| State Street | 2.51% | 13F |
| Two Sigma | 1.51% | 13F |
| Wellington Management | 1.46% | 13F |
| D.E. Shaw | 1.11% | 13F |
| T. Rowe Price | 1.08% | 13F |
Percentages above are of 132,376,000 shares outstanding, as reported by Alnylam Pharmaceuticals, Inc. on its Form 10-K dated December 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Alnylam Pharmaceuticals, Inc.’s 10-K dated December 31, 2025. This page is a static snapshot rebuilt weekly on October 18, 2026; a live search always shows the current data.
At Alnylam Pharmaceuticals, Inc.'s shareholder meeting held May 20, 2026, in the 2025-2026 proxy season, 680 asset managers reported how they voted in their SEC Form N-PX filings, covering 4,659 separate fund positions. Their filings are grouped here into 5 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. Alnylam Pharmaceuticals, Inc.'s own Form 8-K tally for this meeting is published below, but no row in it could be matched to the most widely held item, so this page states no certified outcome for that item. On that item — To approve, in a non-binding advisory vote, the compensation of Alnylam's named executive… — the reporting funds and managers cast 96% of the shares they voted in favour (FOR divided by FOR plus AGAINST plus WITHHELD; abstained and unvoted shares are excluded because neither took a side). Fund and manager reports are combined in it and may count the same shares twice: it adds fund reports to institutional-manager reports, which can cover the same shares. It is not the company's certified result.
Alnylam Pharmaceuticals, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).
Download data (CSV): ballot items · votes by manager · column guide.